Search Results - "Nelsen, Andrew C."

Development of the Pulmonary Hypertension Functional Classification Self-Report: a patient version adapted from the World Health Organization Functional Classification measure by Highland, Kristin B, Crawford, Rebecca, Classi, Peter, Morrison, Ross, Doward, Lynda, Nelsen, Andrew C, Castillo, Howard, Mathai, Stephen C, DuBrock, Hilary M

“…Abstract Background Pulmonary arterial hypertension (PAH) is characterized by progressive limitations on physical activity, right heart failure, and premature…”
Get full text

Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension by Ozen, Gulsev, Benyahia, Chabha, Mani, Salma, Boukais, Kamel, Silverstein, Adam M., Bayles, Richard, Nelsen, Andrew C., Castier, Yves, Danel, Claire, Mal, Hervé, Clapp, Lucie H., Longrois, Dan, Norel, Xavier

“…Background and Purpose In patients with pulmonary hypertension (PH) associated with lung disease and/or hypoxia (Group III), decreased pulmonary vascular tone…”
Get full text

Medullary pain facilitating neurons mediate allodynia in headache-related pain by Edelmayer, Rebecca M., Vanderah, Todd W., Majuta, Lisa, Zhang, En-Tan, Fioravanti, Beatriz, De Felice, Milena, Chichorro, Juliana G., Ossipov, Michael H., King, Tamara, Lai, Josephine, Kori, Shashi H., Nelsen, Andrew C., Cannon, Keri E., Heinricher, Mary M., Porreca, Frank

“…Objective To develop and validate a model of cutaneous allodynia triggered by dural inflammation for pain associated with headaches. To explore neural…”
Get full text

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study by Dean, Bonnie B., Saundankar, Vishal, Stafkey-Mailey, Dana, Anguiano, Rebekah H., Nelsen, Andrew C., Gordon, Kathryn, Classi, Peter

“…Background Given the improved convenience of oral prostacyclins, there is a shift toward their use in treating pulmonary arterial hypertension (PAH)…”
Get full text

Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies by Tonelli, Adriano R., Sahay, Sandeep, Gordon, Kathryn W., Edwards, Lisa D., Allmon, Andrew G., Broderick, Meredith, Nelsen, Andrew C.

“…The 2015 European Society of Cardiology/European Respiratory Society treatment guidelines recommend frequent risk assessment in pulmonary arterial hypertension…”
Get full text

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting by Balasubramanian, Vijay P., Safdar, Zeenat, Sketch, Margaret R., Broderick, Meredith, Nelsen, Andrew C., Lee, Dasom, Melendres‐Groves, Lana

“…Real‐world dosing and titration of parenteral (subcutaneous, SC; intravenous, IV) prostacyclin, a mainstay of pulmonary arterial hypertension (PAH) treatment,…”
Get full text

Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life by DuBrock, Hilary M., Nathan, Steven D., Reeve, Bryce B., Kolaitis, Nicholas A., Mathai, Stephen C., Classi, Peter M., Nelsen, Andrew C., Olayinka-Amao, Bimpe, Norcross, Lindsey N., Martin, Susan A.

“…Pulmonary hypertension resulting from chronic lung disease such as chronic obstructive pulmonary disease and interstitial lung disease is categorized by the…”
Get full text

Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily by Shapiro, Shelley, Mandras, Stacy, Restrepo-Jaramillo, Ricardo, Shen, Eric, Broderick, Meredith, Rao, Youlan, Lee, Dasom, Nelsen, Andrew C.

“…Treprostinil is a prostacyclin approved for the treatment of pulmonary arterial hypertension. Commercial data sets indicate that approximately 20–25% of…”
Get full text

Implantable system for treprostinil: a real-world patient experience study by Shapiro, Shelley, Bourge, Robert C., Pozella, Patti, Harris, David F., Borg, Erick H., Nelsen, Andrew C.

“…Parenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. However, subcutaneous or intravenous delivery via…”
Get full text

Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study by Dean, Bonnie B., Saundankar, Vishal, Stafkey-Mailey, Dana, Anguiano, Rebekah H., Nelsen, Andrew C., Gordon, Kathryn, Classi, Peter

“…Changes within text are indicated in bold…”
Get full text

Dosing characteristics of oral treprostinil in real-world clinical practice by Balasubramanian, Vijay P., Messick, Chad R., Broderick, Meredith, Nelsen, Andrew C.

“…Pharmacokinetic studies with oral treprostinil demonstrate that three times daily (TID) dosing reduces peak-to-trough plasma trepostinil fluctuations compared…”
Get full text

High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients by KAZEEM, Gbenga R, COX, Charles, APONTE, Jennifer, MESSENHEIMER, John, BRAZELL, Celia, NELSEN, Andrew C, NELSON, Matthew R, FOOT, Elizabeth

Get full text

Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension - An analysis of FREEDOM-EV by Benza, Raymond L., Gomberg-Maitland, Mardi, Farber, Harrison W., Vizza, Carmine Dario, Broderick, Meredith, Holdstock, Louis, Nelsen, Andrew C., Deng, Chunqin, Rao, Youlan, White, R. James

“…[Display omitted] Risk scores integrate clinical variables emphasizing symptoms, exercise capacity, and measures of cardiac strain to predict clinical outcome…”
Get full text

The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans by ROBERTS, Patrick J, ROLLINS, Kristan D, KASHUBA, Angela D. M, PAINE, Mary F, NELSEN, Andrew C, WILLIAMS, Eric E, MORAN, Cassandra, LAMBA, Jatinder K, SCHUETZ, Erin G, HAWKE, Roy L

“…The CYP3A5 * 1 allele has been associated with differences in the metabolism of some CYP3A substrates. CYP3A5 polymorphism may also influence susceptibility…”
Get full text

Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms by Mathai, Stephen C, Hemnes, Anna Ryan, Manaker, Scott, Anguiano, Rebekah H, Dean, Bonnie B, Saundankar, Vishal, Classi, Peter, Nelsen, Andrew C, Gordon, Kathryn, Ventetuolo, Corey E

“…Retrospective administrative claims database studies provide real-world evidence about treatment patterns, healthcare resource use, and costs for patients and…”
Get full text

The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis by Vizza, Carmine Dario, Badagliacca, Roberto, Messick, Chad R., Rao, Youlan, Nelsen, Andrew C., Benza, Raymond L.

“…The impact of treatment delay in stable patients with pulmonary arterial hypertension (PAH) remains unaddressed. This meta-analysis included six datasets of…”
Get full text

Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension by Ozen, Gulsev, Benyahia, Chabha, Mani, Salma, Boukais, Kamel, Silverstein, Adam M, Bayles, Richard, Nelsen, Andrew C, Castier, Yves, Danel, Claire, Mal, Hervé, Clapp, Lucie H, Longrois, Dan, Norel, Xavier

“…In patients with pulmonary hypertension (PH) associated with lung disease and/or hypoxia (Group III), decreased pulmonary vascular tone and tissue hypoxia is…”
Get full text

High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients by Kazeem, Gbenga R, Cox, Charles, Aponte, Jennifer, Messenheimer, John, Brazell, Celia, Nelsen, Andrew C, Nelson, Matthew R, Foot, Elizabeth

“…BACKGROUNDSevere cutaneous adverse reactions (SCARs) are associated with over 200 medicines including lamotrigine, an antiepileptic drug. Previous studies have…”
Get full text

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension by Chen, Hubert, Rosenzweig, Erika B, Gotzkowsky, S Karl, Arneson, Carl, Nelsen, Andrew C, Bourge, Robert C

“…Patient treatment satisfaction is likely to be a highly relevant outcome measure in pulmonary arterial hypertension (PAH), a condition for which the benefits…”
Get full text

Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension by Bourge, Robert C, Tapson, Victor F, Safdar, Zeenat, Benza, Raymond L, Channick, Richard N, Rosenzweig, Erika B, Shapiro, Shelley, White, R James, McSwain, Christopher Shane, Gotzkowsky, Stephen Karl, Nelsen, Andrew C, Rubin, Lewis J

“…Inhaled treprostinil is a prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH) that may provide a more convenient treatment…”
Get more information